PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.
